Darbepoetin alfa, an erythropoiesis-stimulating agent (ESA) used to treat renal anemia, might have anti-proteinuric effects in patients with diabetic kidney disease.

The optimal time to measure PSA response to treatment is the one that best predicts metastatic hormone-sensitive prostate cancer (mHSPC) progression.

Prevalence nearly doubled from 2000 to 2020, from 3.40 to 6.53 percent in boys and from 3.02 to 5.82 percent in girls.

(HealthDay News) — A quality improvement (QI) collaborative can reduce rates of missed radiotherapy appointments, according to a study published online Nov. 11 in the Journal of the American College ...

“Elevated leukocyte counts, particularly increased neutrophil counts, and decreased hemoglobin levels, are associated with severe WMHs,” according to Dr Liu’s team. “Our study results highlight the ...

Increase in Medicare revenue for practices adopting RPM mainly due to direct billing for RPM and more outpatient visits.

Researchers examined the association between BMI trajectory and outcomes in renal cell carcinoma using data from the Oncology Research Information Exchange Network.

Medical influencers and social media, having changed the ways in which physicians communicate, now carry certain ethical responsibilities.

(HealthDay News) — Heat- and cold-related mortality account for about 0.1 percent of total U.S. mortality, according to a study published online Nov. 18 in the Annals of Internal Medicine.

After a median 9.6 months of cabozantinib treatment, the 6-month brain metastasis progression-free rate was 56%, meeting the study’s primary endpoint.

11.7 percent of the association was mediated by depression and inflammation, with depression mediating 11.3 percent.